Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries
Biotech Acquisition Company Cl A
(NQ:
BIOT
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EST, Feb 2, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
-
Bid (Size)
10.14 (175)
Ask (Size)
10.20 (44)
Prev. Close
10.15
Today's Range
N/A - N/A
52wk Range
N/A - N/A
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Blade Therapeutics to Participate in “Drug Development in Pulmonary Medicine” Panel Discussion at 2022 BTIG Biotechnology Conference
August 01, 2022
From
Blade Therapeutics, Inc.
Via
Business Wire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
June 03, 2022
Good morning! We're preparing for another busy day of trading with a breakdown of the biggest pre-market stock movers for Friday!
Via
InvestorPlace
Performance
More News
Read More
Blade Therapeutics Presents Preclinical Data Highlighting Differentiating Characteristics of Cudetaxestat at the American Thoracic Society 2022 International Conference
May 18, 2022
From
Blade Therapeutics, Inc.
Via
Business Wire
Blade Therapeutics Presents Data from Phase 1 and Preclinical Studies of Cudetaxestat at the American Thoracic Society 2022 International Conference
May 16, 2022
From
Blade Therapeutics, Inc.
Via
Business Wire
Blade Therapeutics Announces Feedback from FDA on End-of-Phase 1 Data Package
April 04, 2022
From
Blade Therapeutics, Inc.
Via
Business Wire
Blade Therapeutics to Present Data from Preclinical and Phase 1 Studies of Cudetaxestat at the American Thoracic Society 2022 International Conference
March 24, 2022
From
Blade Therapeutics, Inc.
Via
Business Wire
Blade Therapeutics Announces Successful Completion of Phase 1 Clinical Study that Evaluated Co-Administration of Cudetaxestat with Either of Two Approved Therapies for Idiopathic Pulmonary Fibrosis
January 12, 2022
From
Blade Therapeutics, Inc.
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.